Co
Non verificato

Compass Pathfinder Limited

Di cosa scriviamo

BiotecnologiaFarmaceuticaPsichiatriaSaluteScienza
18/04/2026
Industria
Scienza
Psichiatria
Igiene alimentare
Medicina - Varie
Politica Interna
Biotecnologia
Farmaceutica
Salute
Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments
1.00
08/04/2026
Eventi
Web e Social Network
Biotecnologia
Medicina alternativa
Igiene alimentare
Sanità
Salute
Farmaceutica
Psichiatria
Scienza
Medicina - Varie
Compass Pathways to Attend Needham Virtual Healthcare Conference on April 14, 2026
1.00
07/04/2026
Mercato del lavoro
Scienza
Psichiatria
Finanza
Banca
Medicina - Varie
Associazioni/Professionisti
Biotecnologia
Farmaceutica
Salute
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1.00
24/03/2026
Mercato azionario
Scienza
Psichiatria
Igiene alimentare
Medicina - Varie
Biotecnologia
Medicina alternativa
Farmaceutica
Salute
Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights
1.00
12/03/2026
Eventi
Web e Social Network
Medicina alternativa
Psichiatria
Salute
Scienza
Biotecnologia
Compass Pathways to Present at Stifel 2026 Virtual CNS Forum on March 18, 2026
1.00
26/02/2026
Scienza
Psichiatria
Finanza
Associazioni/Professionisti
Biotecnologia
Medicina alternativa
Farmaceutica
Salute
Compass Pathways Announces Exercise of $200 Million in Outstanding Warrants
1.00
24/02/2026
Eventi
Web e Social Network
Scienza
Biotecnologia
Farmaceutica
Salute
Psichiatria
Compass Pathways to attend TD Cowen 46th Annual Healthcare Conference in Boston, MA from March 2-4, 2026
1.00
19/02/2026
Scienza
Sanità
Associazioni/Professionisti
Farmaceutica
Psichiatria
Medicina - Varie
Biotecnologia
Igiene alimentare
Finanza
Salute
Compass Pathways Announces Pricing of $150 Million Public Offering
1.00
17/02/2026
Biotecnologia
Igiene alimentare
Sanità
Salute
Farmaceutica
Psichiatria
Scienza
Medicina - Varie
Mercato azionario
Compass Pathways Launches Proposed $150.0 Million Public Offering
1.00
17/02/2026
Web e Social Network
Industria
Biotecnologia
Igiene alimentare
Sanità
Salute
Farmaceutica
Psichiatria
Scienza
Medicina - Varie
Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
1.00

Recapiti

Social Media

Seguaci
0
Compatibilità
0